TrialPloS one2018

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.

Javier Morales-Ramirez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.